Daniil Stroyakovskiy
Overview
Explore the profile of Daniil Stroyakovskiy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
7546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oaknin A, Lee J, Makker V, Oh D, Banerjee S, Gonzalez-Martin A, et al.
Adv Ther
. 2025 Mar;
PMID: 40048102
of the original article, 'Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02'. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate, which...
2.
Fasching P, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley D, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 40019493
Purpose: The phase 3 NATALEE trial reported a statistically significant invasive disease-free survival benefit with ribociclib plus nonsteroidal aromatase inhibitor (NSAI) versus an NSAI alone in stage II/III hormone receptor-positive,...
3.
Oaknin A, Lee J, Makker V, Oh D, Banerjee S, Gonzalez-Martin A, et al.
Adv Ther
. 2024 Sep;
41(11):4125-4139.
PMID: 39261417
Introduction: DESTINY-PanTumor02 (NCT04482309) evaluated the efficacy and safety of trastuzumab deruxtecan (T-DXd) in pretreated patients with human epidermal growth factor receptor 2 (HER2)-expressing [immunohistochemistry (IHC) 3+/2+] solid tumors across seven...
4.
Prager G, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al.
Future Oncol
. 2024 Jul;
20(36):2823-2832.
PMID: 38953855
What Is This Summary About?: This is a summary describing the results from a phase 3 clinical trial called SUNLIGHT. The study looked at treatment with orally administered trifluridine/tipiracil plus...
5.
Cho B, Lu S, Felip E, Spira A, Girard N, Lee J, et al.
N Engl J Med
. 2024 Jun;
391(16):1486-1498.
PMID: 38924756
Background: Amivantamab plus lazertinib (amivantamab-lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC). Methods:...
6.
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al.
N Engl J Med
. 2024 Mar;
390(12):1080-1091.
PMID: 38507751
Background: Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Whether this...
7.
Meric-Bernstam F, Makker V, Oaknin A, Oh D, Banerjee S, Gonzalez-Martin A, et al.
J Clin Oncol
. 2023 Oct;
42(1):47-58.
PMID: 37870536
Purpose: Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non-small-cell lung cancer. Treatments are limited for...
8.
Slamon D, Fasching P, Hurvitz S, Chia S, Crown J, Martin M, et al.
Ther Adv Med Oncol
. 2023 Jun;
15:17588359231178125.
PMID: 37275963
Background: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer. New...
9.
Prager G, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al.
N Engl J Med
. 2023 May;
388(18):1657-1667.
PMID: 37133585
Background: In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients with metastatic colorectal cancer. Preliminary data from single-group and randomized phase 2 trials suggest...
10.
Ascierto P, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al.
Lancet Oncol
. 2022 Dec;
24(1):33-44.
PMID: 36460017
Background: Primary analysis of the phase 3 IMspire150 study showed improved investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in...